1. 1302TiPCA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. (23rd October 2018) Authors: Lipson, E J; Long, G V; Tawbi, H; Schadendorf, D; Atkinson, V G; Maurer, M; Simonsen, K L; Harbison, C; Hodi, F S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗